Guillain–barre syndrome (GBS) rise in complications due to diagnostic pitfalls: A case report
DOI:
https://doi.org/10.70066/jahm.v13i3.1629Keywords:
Guillain-Barre syndrome, Intravenous Immunoglobulins, diagnostic pitfallsAbstract
Guillain-Barre syndrome (GBS) is an abrupt, complex degenerative neurological condition that can manifest as either acute or chronic. It has been observed that antecedent infections serve as significant risk factors for acquiring GBS, in current case study we observed the antecedent infection of Chikungunya virus and recent history of Covid 19 vaccination. Although the aetiology is yet unknown, the pathophysiology demonstrates demyelination of the spinal nerve roots, which is marked by muscle stiffness and symmetrical limb paralysis.In cases of severity, early diagnosis and immediate treatment are crucial. Here we discuss the case of GBS with complications due to diagnostic pitfalls. This case study focuses on 60 years old male patient exhibiting the complaints of paraesthesia in lower limb and increasing muscle weakness.In this case firstlythe patient was misdiagnosed with appearance of small hypodensity in left caudate nucleus in CT scan study of brain. After one week patient’s conditions was getting worseand shifted to another hospital for further diagnosis and treatment. After thatin radiological examination of brain (CT scan) atrophic alterations were seen.Cerebrospinal fluid analysis and Nerve Conduction Velocity study showed demyelinating polyradiculoneuropathy like AIDP type of GBS.In this case study patient was treated with intravenous immunoglobulin (IVIG) transfusion for 5 days and progress of slight movements of limbs was observed.The significance of precise diagnosis and prompt implementation of suitable treatment approaches in the management of GBS is highlighted by this case study.
References
Mulroy, E., & Anderson, N. E. (2020). Altered mental status in “Guillain‐Barré syndrome”–a noteworthy clinical clue. Annals of Clinical and Translational Neurology, 7(12), 2489-2507. https://doi.org/10.1002/acn3.51226
Bucciol, G., Moens, L., Bosch, B., Bossuyt, X., Casanova, J. L., Puel, A., & Meyts, I. (2019). Lessons learned from the study of human inborn errors of innate immunity. The Journal of allergy and clinical immunology, 143(2), 507–527. https://doi.org/10.1016/j.jaci.2018.07.013
Stojanov, A., Berisavac, I., Bozovic, I., Arsenijevic, M., Lukic‐Rajic, S., Petrovic, M., ... & Peric, S. (2020). Incidence and mortality rates of Guillain‐Barré syndrome in Serbia. Journal of the Peripheral Nervous System, 25(4), 350-355. https://doi.org/10.1111/jns.12412
Begum, S. A., Kumar, T. V., Rahaman, S. A., Rani, S. J., Kosanam, S., & Veena, Y. (2022). Gullian barr syndrome-a rare disease case report. Research Journal of Pharmacology and Pharmacodynamics, 14(4), 234-236. http://dx.doi.org/10.52711/2321-5836.2022.00040
Zavitrenko, D., Rizhniak, R., Snisarenko, I., Pasichnyk, N., Babenko, T., & Berezenko, N. (2022). Specifics of Speech Development of Children with Cerebral Palsy. International Journal of Computer Science & Network Security, 22(11), 157-162. https://doi.org/10.22937/IJCSNS.2022.22.11.22
Sonawane, A., Jawale, G., Devhadrao, N., Bansode, A., Lokhande, J., Kherade, D., ... & Tare, H. (2023). Formulation and development of mucoadhesive nasal drug delivery of ropinirol hcl for brain targeting. International Journal of Applied Pharmaceutics, 15(5), 325-332. https://dx.doi.org/10.22159/ijap.2023v15i5.48437
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-barré syndrome. The lancet, 397(10280), 1214-1228. https://doi.org/10.1016/S0140-6736(21)00517-1
Madden, J., Spadaro, A., Koyfman, A., & Long, B. (2024). High risk and low prevalence diseases: Guillain-Barré syndrome. The American Journal of Emergency Medicine, 75, 90-97. https://doi.org/10.1016/j.ajem.2023.10.036
Lu, X., Ding, K., Fang, Z., Liu, Y., Ji, T., Sun, J., ... & He, L. (2024). Lateral Flow Biosensor for On-Site Multiplex Detection of Viruses Based on One-Step Reverse Transcription and Strand Displacement Amplification. Biosensors, 14(2), 103. https://doi.org/10.3390/bios14020103
Koike, H., Chiba, A., & Katsuno, M. (2021). Emerging infection, vaccination, and Guillain–Barré syndrome: a review. Neurology and therapy, 10(2), 523-537. https://doi.org/10.1007/s40120-021-00261-4
van Doorn, P. A., Van den Bergh, P. Y., Hadden, R. D., Avau, B., Vankrunkelsven, P., Attarian, S., ... & Willison, H. J. (2023). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. Journal of the Peripheral Nervous System, 28(4), 535-563. https://doi.org/10.1111/jns.12594
Lupu, V. V., Miron, I., Cianga, A. L., Gavrilovici, C., Grigore, I., David, A. G., ... & Lupu, A. (2022). Diagnostic pitfalls in Guillain–Barré syndrome: case report and literature review. Children, 9(12), 1969. https://doi.org/10.3390/children9121969
Lee, J. H., & Hwang, K. K. (2022). End-of-life care for end-stage heart failure patients. Korean Circulation Journal, 52(9), 659-679. https://doi.org/10.4070/kcj.2022.0211
Morales-Ruiz, V., Juarez-Vaquera, V. H., Rosetti-Sciutto, M., Sanchez-Munoz, F., & Adalid-Peralta, L. (2022). Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis. Autoimmunity Reviews, 21(3), 103019. https://doi.org/10.1016/j.autrev.2021.103019
Cerny, T., Schwarz, M., Schwarz, U., Lemant, J., Gérardin, P., & Keller, E. (2017). The range of neurological complications in chikungunya fever. Neurocritical care, 27, 447-457. https://doi.org/10.1007/s12028-017-0413-8
Chirinos, J. S., Alva-Diaz, C., Quispe-Vicuña, C., Salvador-Oscco, E., Capcha-Jimenez, U., Javier-Murillo, N., ... & Mori, N. (2024). Bilateral medial medullary infarction mimicking Guillain‐Barré Syndrome (GBS): Case report and qualitative systematic review. Stroke: Vascular and Interventional Neurology, 4, e12984_077. https://doi.org/10.1161/SVIN.04.suppl_1.077
Levison, L. S., Thomsen, R. W., Markvardsen, L. K., Christensen, D. H., Sindrup, S. H., & Andersen, H. (2020). Pediatric Guillain-Barré syndrome in a 30-year nationwide cohort. Pediatric Neurology, 107, 57-63. https://doi.org/10.1016/j.pediatrneurol.2020.01.017
Peña, L., Moreno, C. B., & Gutierrez-Alvarez, A. M. (2015). Pain management in Guillain–Barre syndrome: a systematic review. Neurología (English Edition), 30(7), 433-438. https://doi.org/10.1016/j.nrleng.2014.04.001
Kerr, J., Quinti, I., Eibl, M., Chapel, H., Späth, P. J., Sewell, W. C., ... & Peter, H. H. (2014). Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Frontiers in immunology, 5, 629. https://doi.org/10.3389/fimmu.2014.00629
Ghimire A, Kunwar B, Aryal B, Gaire A, Bist A, Shah B, Mainali A, Ghimire B, Gajurel BP. Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysis. Journal of Clinical Neuroscience. 2024 Mar 1;121:1-0. https://doi.org/10.1016/j.jocn.2024.01.025
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Snehal Gojare, Sumit Deore
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The author(s) will retain copyright and permit the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that permits others to share the work with an acknowledgment of the author and initial publication in this journal.
The entire contents of the JAHM are protected under Indian and international copyrights. The Journal, however, allows free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute works in any online website for any non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also permits the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
In case of JAHM does not publish said work, the author(s) will be so notified and all rights assigned hereunder will be given back to the author(s).
All accepted works should not be published anywhere without prior written permission from JAHM. The author(s) hereby declare that they are sole author(s) of the work, that all authors have contributed and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work has been submitted to another journal.
